口服选择性雌激素受体降解剂用于乳腺癌治疗:专注于药理上的差异
Roberta Scafetta1,2, Paola Zagami1,3, Marzia Del Re4,5
1Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology IRCCS, Milan, Italy.
Breast cancer research and treatment
|January 8, 2025
概括
新型口服选择性雌激素受体降解剂 (SERDs) 显示出治疗激素受体阳性乳腺癌 (HR + BC) 的前景,该癌症对内分泌疗法 (ET) 具有抗性. 这些药物为患有晚期疾病的患者提供了新的希望.
科学领域:
- 在瘤学瘤学.
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 激素受体阳性乳腺癌 (HR+BC) 管理依赖于内分泌疗法 (ET) 针对雌激素受体 (ER) 信号.
- ET是有效的,但经常遇到抵抗,导致疾病的进展.
- 雌激素受体1 (ESR1) 基因突变可以驱动对ET的抗性.
研究的目的:
- 审查关于HR+BC治疗新型口服选择性雌激素受体降解剂 (SERD) 的现有证据.
- 检查口服SERDs在克服治疗耐药性的潜力.
- 提供关于口服SERD的最新发现的概述.
主要方法:
- 在PubMed,EMBASE和Scopus数据库中的系统文献搜索.
- 对HR+BC.口服SERDs的证据的审查.
- 分析作用机制,安全性,药理动力学和药理动力学.
主要成果:
- 身体ESR1突变维持ER活动并促进ET耐药性.
- 用ET和CDK4/6抑制剂治疗失败是一个重大的临床挑战.
- 新的口服SERD正在作为单一治疗和组合治疗进行探索.
结论:
- 口服SERD是一种有前途的治疗策略,用于克服HR+BC的ET抵抗.
- 这些药物有可能改善晚期或耐火性疾病患者的治疗结果.
- 进一步调查它们的有效性,安全性和最佳使用是有必要的.
相关概念视频
Transducer Mechanism: Nuclear Receptors
1.3K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
1.3K
Dose-Response Relationship: Selectivity and Specificity
6.4K
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and...
6.4K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Internal Receptors
69.4K
Many cellular signals are hydrophilic and therefore cannot pass through the plasma membrane. However, small or hydrophobic signaling molecules can cross the hydrophobic core of the plasma membrane and bind to internal, or intracellular, receptors that reside within the cell. Many mammalian steroid hormones use this mechanism of cell signaling, as does nitric oxide (NO) gas.
69.4K
Structure-Activity Relationships and Drug Design
494
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
494
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
133
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
133


